We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Events

26 Oct 2026 - 29 Oct 2026
16 Nov 2026 - 19 Nov 2026

CVD Risk Prediction Tool Could Guide Statin Therapy

By HospiMedica International staff writers
Posted on 18 Sep 2025

Cardiovascular disease (CVD) remains one of the leading causes of morbidity and mortality, making accurate risk assessment essential for guiding preventive therapy. More...

Existing tools, such as the Pooled Cohort Equations (PCEs), are widely used, but their thresholds for treatment recommendations may not fully capture patient risk. Now, researchers have developed a new predictive model to refine decision-making, particularly around the use of statin therapy for primary prevention.

Researchers at Northwestern Medicine (Chicago, IL, USA) have created the PREVENT (Predicting Risk of cardiovascular disease EVENTs) risk equations, initially developed for the American Heart Association in 2023. These equations aim to more accurately estimate CVD risk compared with prior models. The tool provides updated thresholds for when clinicians should consider prescribing statins, supporting shared decision-making between patients and healthcare providers.

In the latest study, the researchers conducted a cross-sectional analysis of more than 5,200 U.S. adults aged 40 to 75 from the National Health and Nutrition Examination Surveys. Representing 133 million adults, the study showed that 28.1 million were already on statins and 15.2 million were eligible due to existing high-risk conditions. Of the remaining population, PREVENT identified 11.8 million additional individuals who would benefit from statin therapy with a 10-year CVD risk of 5 percent or greater.

The findings, published in JAMA Cardiology, demonstrated that PREVENT not only detects risk more accurately but also identifies a “sweet spot” at 3 to 5 percent 10-year risk, where the greatest benefit from lipid-lowering medication occurs. This could reshape treatment recommendations by ensuring patients most likely to benefit are prioritized, while lower-risk individuals receive more personalized discussions. Future work will focus on improving risk communication strategies to support patient understanding and adherence.

“If a clinician can have a conversation with their patient explaining that there is a certain threshold after which intervention is recommended because the benefit of starting the intervention is greater than any potential harm, this is often a concept patients understand and can help make them more confident in the decision to adhere to their providers’ recommendations,” said Sadiya Khan, MD, MSc, lead author of the study.

Related Links:
Northwestern Medicine


Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Resorbable Bovine Collagen Membrane
GenDerm
Surgical System
Stealth AXiS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Half-matched bone marrow transplant expands access to curative treatment for children and young adults with severe aplastic anemia. (Photo courtes of Margarita Dionysiou using Bio Render)

Half-Matched Family Donors Could Expand Transplant Access for Severe Aplastic Anemia

Severe aplastic anemia is a rare, life-threatening disorder in which the bone marrow fails to produce enough healthy blood cells, leaving children and young adults vulnerable to anemia, infection, and bleeding.... Read more

Patient Care

view channel
Image: Researchers evaluated the Omni 128 cm long-axial field-of-view PET/CT system, which captures more of the body and radiotracer signal at once, potentially enabling shorter scans. (Photo courtesy of GE HealthCare)

Total-Body PET/CT Scanner Enables One-Minute Diagnostic-Quality Cancer Imaging

Positron emission tomography/computed tomography (PET/CT) combines radiotracer-based functional imaging with anatomical detail to diagnose, stage, and monitor cancer. Conventional scanners image the body... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.